EGFR-Positive NSCLC Treatment: Combination Therapies in FLAURA2, MARIPOSA, and PAPILLON Improve Progression-Free Survival, But Increase Toxicity

Recent clinical trials are changing the landscape of treatment for patients with EGFR-positive non-small cell lung cancer (NSCLC). The studies, FLAURA2, MARIPOSA, and PAPILLON, reveal combination therapies are improving progression-free survival compared to single-agent oral treatments. However, these combination approaches also present increased challenges regarding toxicity, treatment discontinuation, and adverse effects. Specifically, the FLAURA2 trial investigated osimertinib combined with chemotherapy. The MARIPOSA study examined amivantamab in conjunction with lazertinib. The PAPILLON trial also studied amivantamab plus lazertinib. These trials all suggest that combining targeted therapies with other treatments extends the time patients live without their cancer progressing. On the other hand, researchers observed that the combination therapies led to higher rates of side effects, causing some patients to stop treatment or experience negative health outcomes.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Author

Mark Chiang